Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

News

Alternating vaccines trial expands to include two additional vaccines

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

Today, the medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine. Both the UK's Medicines and Healthcare products Regulatory Agency (MHRA) and the EU's European Medicines Agency have concluded that whilst there was a possible link from these very rare blood clots to the vaccine, the benefits of vaccination continue to outweigh the risks in all age groups, and have requested the product information is updated to mitigate further risks.

AstraZeneca publish primary analysis from US trial of coronavirus vaccine

Our partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.

Marking 100 years of the tuberculosis BCG vaccine

The VALIDATE Network, a community of over 400 researchers based in more than 200 research institutions in 63 countries, will today launch the “BCG100 Programme” marking the centenary of the Bacille Calmette-Guérin Vaccine for tuberculosis. BCG100 officially launches with the ‘BCG Then and Now’ online lecture by Professor Helen McShane, VALIDATE Network Director and Jenner Investigator and Professor Paul Fine, London School of Hygiene and Tropical Medicine. Taking place at 6pm GMT, 24 March 2021, the talk will cover the initial development of the vaccine, moving through to the modern-day challenges in the fight against TB and the future challenges researchers face in replacing the enduring BCG vaccine.

More news

COVID OUTBREAK

During the COVID-19 pandemic, the Jenner Institute is taking measures to prevent the spread of the disease. Departments are instructed by the University’s Registrar to continue to work from home where possible, and manage the return to on site working, based on the University guidelines for risk assessments and work prioritisation. This is to restrict contact between individuals as far as possible. The University remains open and operating as far as possible with the following restrictions:

- No public access to the University.

- On-site activity permitted where it cannot be undertaken remotely, driven by safety, capacity and other factors such as schools reopening/other changes in government guidelines.

- Teaching and assessment are undertaken remotely where possible and, depending on government guidelines, gatherings of staff and students only permitted where essential for teaching and assessment to take place.

UPDATE ON COVID-19 VACCINE Trial

For all information and enquiries regarding the COVID-19 vaccine trial, please visit: https://covid19vaccinetrial.web.ox.ac.uk/.

COVID-19 Response

- Protect our community

- Protect the vulnerable

- Protect yourself

To find out more about the University's COVID-19 response and measures of protection: 

COVID-19 response

SUPPORT OXFORD’S COVID-19 VACCINE RESEARCH

Funding for Oxford’s COVID-19 vaccine research requires unprecedented speed, scope and ambition. Support from Government, corporations, trusts and foundations will be crucial to the development of a vaccine to combat the new virus. Alongside those traditional sources of funding, philanthropic donations of any size will have real and rapid impact, allowing us to accelerate this time-critical research, and ensure that Oxford’s vaccine solution will be as effective and swift as possible.

If you are interested in supporting this effort, please make a gift here.

Public Engagement